Patient-derived induced pluripotent stem cells (iPSCs) have become a promising resource for exploring genetics of complex diseases, discovering new drugs, and advancing regenerative medicine. Increasingly, laboratories are creating their own banks of iPSCs derived from diverse donors. However, there are not yet standardized guidelines for qualifying these cell lines, i.e., distinguishing between bona fide human iPSCs, somatic cells, and imperfectly reprogrammed cells. Here, we report the establishment of a panel of 30 iPSCs from CD34 peripheral blood mononuclear cells, of which 10 were further differentiated in vitro into all three germ layers. We characterized these different cell types with commonly used pluripotent and lineage specific markers, and showed that NES, TUBB3, and OTX2 cannot be reliably used as ectoderm differentiation markers. Our work highlights the importance of marker selection in iPSC authentication, and the need for the field to establish definitive standard assays.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570500PMC
http://dx.doi.org/10.1016/j.scr.2019.101434DOI Listing

Publication Analysis

Top Keywords

evaluation commonly
4
commonly ectoderm
4
ectoderm markers
4
markers ipsc
4
ipsc trilineage
4
trilineage differentiation
4
differentiation patient-derived
4
patient-derived induced
4
induced pluripotent
4
pluripotent stem
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!